Zobrazeno 1 - 10
of 26
pro vyhledávání: '"S D, Berkowitz"'
Autor:
M Szarek, E S Debus, M R Nehler, S S Anand, M R Patel, L P Haskell, E S Muehlhofer, S D Berkowitz, R M Bauersachs, M P Bonaca
Publikováno v:
European Heart Journal. 43
Background In the VOYAGER PAD trial, rivaroxaban reduced first and total (first and subsequent) occurrences of major adverse limb and cardiovascular events in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)
Autor:
T I De Vries, J W Eikelboom, J Bosch, J Westerink, J A N Dorresteijn, M Alings, L Dyal, S D Berkowitz, Y Van Der Graaf, K A A Fox, F L J Visseren
Publikováno v:
European Heart Journal. 40
Background The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial has demonstrated that adding low-dose rivaroxaban to aspirin in patients with stable atherosclerotic disease on average reduces recurrence of cardiovas
Publikováno v:
Acta anaesthesiologica Scandinavica. 57(5)
Patients receiving anticoagulants could be at higher risk of compressive haematoma with neuraxial anaesthesia use. The phase III RECORD programme compared rivaroxaban with enoxaparin for prevention of venous thromboembolism after total hip or knee re
Autor:
S D, Berkowitz, D C, Sane, K N, Sigmon, J H, Shavender, R A, Harrington, J E, Tcheng, E J, Topol, R M, Califf
Publikováno v:
Journal of the American College of Cardiology. 32(2)
This study sought to determine the frequency of thrombocytopenia and its relation with clinical outcomes in high risk patients undergoing percutaneous coronary revascularization who received either the platelet glycoprotein (GP) IIb/IIIa receptor ant
Autor:
J S, Mandak, J C, Blankenship, L H, Gardner, S D, Berkowitz, F V, Aguirre, K N, Sigmon, G C, Timmis, I C, Gilchrist, M, McIvor, J, Resar, B H, Weiner, B S, George, J D, Talley, A M, Lincoff, J E, Tcheng, R M, Califf, E J, Topol
Publikováno v:
Journal of the American College of Cardiology. 31(7)
This study was designed to identify potential predictors of vascular access site (VAS) complications in the large-scale Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis (IMPACT) II trial, which studied angioplasty with versus witho
Autor:
D B, Mark, P A, Cowper, S D, Berkowitz, L, Davidson-Ray, E R, DeLong, A G, Turpie, R M, Califf, B, Weatherley, M, Cohen
Publikováno v:
Circulation. 97(17)
In the ESSENCE trial, subcutaneous low-molecular-weight heparin (enoxaparin) reduced the 30-day incidence of death, myocardial infarction, and recurrent angina relative to intravenous unfractionated heparin in 3171 patients with acute coronary syndro
Publikováno v:
The Journal of Higher Education. 71:269
Publikováno v:
Educational Researcher. 28:28
Autor:
David Knoke, S. D. Berkowitz
Publikováno v:
Contemporary Sociology. 21:27
Publikováno v:
Revue Française de Sociologie. 31:149